GIP receptor agonism — what is it actually contributing in dual and triple agonists?

GLP-1 gets all the attention, but GIP is the other half of tirzepatide and part of retatrutide. What is the GIP component believed to add on top of GLP-1 activity, and is the science settled on that? Looking for a nuanced, cited discussion.